Trial Profile
Phase III trial of Prophage, a HSPPC-96 Vaccine (Vitespen) for newly diagnosed Glioblastoma Multiforme
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Vitespen (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 21 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jul 2016, as per Agenus media release.
- 16 Apr 2015 New trial record